High court mulls suits regarding flaws in generic drug design

12/2/2012 | Reuters · Las Vegas Sun

The U.S. Supreme Court will hear Mutual Pharmaceutical's appeal to overturn a $21 million jury award to a woman who experienced burnlike lesions and near-blindness after taking the company's generic sulindac, a nonsteroidal anti-inflammatory drug. The generic-drug-maker maintains that federal law regarding generic drug design and labeling precludes civil suits. The Supreme Court's decision on the case is due by June.

View Full Article in:

Reuters · Las Vegas Sun

Published in Brief: